Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryMar032015	Fate Therapeutics Expands and Strengthens Leadership Team SAN DIEGO, March 3, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced that Wendy Levin, M.D., M.S. Read All »	View HTML Fate Therapeutics Expands and Strengthens Leadership Team 14.6 KB
Toggle SummaryFeb252015	Fate Therapeutics to Present at Cowen & Company 35th Annual Health Care Conference SAN DIEGO, Feb. 25, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced that Christian Weyer, M.D., M.A.S., President and Read All »	View HTML Fate Therapeutics to Present at Cowen & Company 35th Annual Health Care Conference 10.5 KB
Toggle SummaryFeb052015	Fate Therapeutics to Present at the 2015 Leerink Global Healthcare Conference SAN DIEGO, Feb. 5, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced that Christian Weyer, M.D., M.A.S., President and Read All »	View HTML Fate Therapeutics to Present at the 2015 Leerink Global Healthcare Conference 10.5 KB
Toggle SummaryJan122015	Fate Therapeutics Announces Key 2015 Objectives for the Advancement of Programmed Cellular Therapeutics Pipeline Primary Endpoint Read-outs from Adult PUMA and Pediatric PROMPT Studies of PROHEMA in Hematologic Malignancies Expected in mid-2015 Topline Data from Pediatric PROVIDE Study of PROHEMA in Rare Inherited Metabolic Disorders Expected in 2015 IND Filing for New Programmed Mobilized Peripheral Blood Read All »	View HTML Fate Therapeutics Announces Key 2015 Objectives for the Advancement of Programmed Cellular Therapeutics Pipeline 22.5 KB
Toggle SummaryJan062015	Fate Therapeutics to Present at Biotech Showcase 2015 SAN DIEGO, Jan. 6, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced that Christian Weyer, M.D., M.A.S., President and Read All »	View HTML Fate Therapeutics to Present at Biotech Showcase 2015 10.6 KB
Toggle SummaryDec182014	Fate Therapeutics Announces Interim Data From Ongoing Phase 2 PUMA Study Key Metrics of Neutrophil Engraftment Improved in PROHEMA Arm Independent Data Monitoring Committee Supports Continuation of Study Enrollment Full Results on Primary Efficacy Endpoint Expected in mid-2015 SAN DIEGO, Dec. 18, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. Read All »	View HTML Fate Therapeutics Announces Interim Data From Ongoing Phase 2 PUMA Study 24.4 KB
Toggle SummaryDec082014	Fate Therapeutics Highlights Effects of Nutrient-Rich Media on Ex Vivo Programmed CD34+ Cells Sourced From Umbilical Cord Blood SAN DIEGO , Dec. 8, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, will present today an overview of the effects of using its nutrient-rich media (NRM) Read All »	View HTML Fate Therapeutics Highlights Effects of Nutrient-Rich Media on Ex Vivo Programmed CD34+ Cells Sourced From Umbilical Cord Blood 22.4 KB
Toggle SummaryDec062014	Fate Therapeutics Unveils Preclinical Findings of Newly-Identified Small Molecule Modulator Combination for Ex Vivo Programming of Mobilized Peripheral Blood Expression of Genes Involved in T-cell Function and Hematopoietic Stem Cell Engraftment Significantly Increased Read All »	View HTML Fate Therapeutics Unveils Preclinical Findings of Newly-Identified Small Molecule Modulator Combination for Ex Vivo Programming of Mobilized Peripheral Blood 22.9 KB
Toggle SummaryNov252014	Fate Therapeutics to Present at Piper Jaffray 26th Annual Healthcare Conference SAN DIEGO, Nov. 25, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that Christian Weyer, M.D., M.A.S., President and Chief Executive Officer, Read All »	View HTML Fate Therapeutics to Present at Piper Jaffray 26th Annual Healthcare Conference 10.8 KB
Toggle SummaryNov112014	Fate Therapeutics Reports Third Quarter 2014 Financial Results Phase 1b PROMPT Study in Pediatric Hematologic Malignancies Open for Enrollment Second Data Review in Phase 2 PUMA Study Expected in 4Q14 Presenting Effects of Ex Vivo Programming on Mobilized Peripheral Blood at ASH SAN DIEGO, Nov. 11, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. Read All »	View HTML Fate Therapeutics Reports Third Quarter 2014 Financial Results 30.1 KB

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.